Cover Image
市場調查報告書

老年癡呆症:全球臨床實驗趨勢

Alzheimer's Disease Global Clinical Trials Review, H1, 2017

出版商 GlobalData 商品編碼 222294
出版日期 內容資訊 英文 833 Pages
訂單完成後即時交付
價格
Back to Top
老年癡呆症:全球臨床實驗趨勢 Alzheimer's Disease Global Clinical Trials Review, H1, 2017
出版日期: 2017年03月31日 內容資訊: 英文 833 Pages
簡介

本報告提供老年癡呆症治療藥相關之臨床實驗最新趨勢分析,提供您G7 (主要7國) 及E7 (新興7國) 各國的臨床實驗數量,並彙整受驗人數,有潛力的贊助商,參與臨床實驗的主要企業和機關,有潛力的藥劑等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要國家的臨床實驗數量
    • 中南美的主要5個國家臨床實驗數量

G7各國臨床實驗數量:中樞神經系統疾病治療藥臨床實驗上老年癡呆症的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:中樞神經系統疾病治療藥臨床實驗上老年癡呆症的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

一定期間所採用的實驗對像

贊助商類別的臨床實驗數量

有潛力的贊助商

老年癡呆症治療藥臨床實驗主要的參與企業

有潛力的藥劑

最新臨床實驗新聞

臨床實驗簡介概要

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

GlobalData's clinical trial report, "Alzheimer's Disease Global Clinical Trials Review, H1, 2017" provides an overview of Alzheimer's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Five Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials 20
  • Clinical Trials by Phase in E7 Countries 22
  • Clinical Trials in E7 Countries by Trial Status 23
  • Clinical Trials by Phase 24
  • In Progress Trials by Phase 25
  • Clinical Trials by Trial Status 26
  • Clinical Trials by End Point Status 27
  • Subjects Recruited Over a Period of Time 28
  • Clinical Trials by Sponsor Type 29
  • Prominent Sponsors 30
  • Top Companies Participating in Alzheimer's Disease Therapeutics Clinical Trials 31
  • Prominent Drugs 32
  • Latest Clinical Trials News on Alzheimer's Disease 33
  • Mar 20, 2017: Corium Reports Positive Progress in Pilot Bioequivalence Study of Once-Weekly Corplex Donepezil Patch 33
  • Mar 16, 2017: QR Pharma Presents New Data on Posiphen in Alzheimer's and Parkinson's Disease at the 13th AD/PD International Conference 33
  • Mar 15, 2017: Longeveron Achieves Milestone in Groundbreaking Stem Cell Trial for Alzheimer's Disease 33
  • Mar 10, 2017: Nature Cell Started Commercial Clinical Trials Phase I and II 'ASTROSTEM,' Stem Cell Drug for Alzheimers Disease Treatment in US 34
  • Mar 08, 2017: TGA Regulatory Approval Received for Alzheimer's Phase II Trial 34
  • Mar 08, 2017: Diabetes drug shows promise for safely treating, detecting Alzheimers disease 35
  • Mar 07, 2017: Phase II Clinical Trial for Treatment of Mild Alzheimer's Disease 35
  • Mar 06, 2017: BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer 35
  • Mar 06, 2017: MorphoSys Partner to Start New Phase 3 Clinical Trials with Gantenerumab in Alzheimer's Disease 36
  • Mar 01, 2017: Luye Pharma Group: Announcement Approval To Commence Clinical Trials For Rivastigmine Multi-Day Transdermal Patch In Germany 36
  • Feb 28, 2017: AC Immune Partner Genentech To Start Second Phase 3 Clinical Trial For Alzheimer's Therapy Crenezumab 36
  • Feb 28, 2017: Accera Announces Results of its First Phase 3 Study in Mild-to-Moderate Alzheimer's 37
  • Feb 19, 2017: BIIB076 Moves into Phase 1 for Alzheimer Disease 37
  • Feb 14, 2017: Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer's Disease to Stop for Lack of Efficacy 38
  • Feb 14, 2017: Cantabio Pharmaceuticals to Present Results from Its Tau Protein Targeting Therapeutic Program for the Treatment of Alzheimers Disease at the 13th International Conference on Alzheimer's and Parkinson's Disease 38
  • Feb 13, 2017: Alzheon to Present New Clinical Data and Analyses for ALZ-801 and Its Active Molecule Tramiprosate at the 13th International Conference on Alzheimer's and Parkinson's Diseases 39
  • Feb 09, 2017: Xanamem research published in prestigious medical journal 39
  • Feb 03, 2017: Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer's Treatment 39
  • Jan 26, 2017: New drug SAK3 may offer hope to Alzheimer's disease patients 40
  • Jan 25, 2017: ORYZON to present ORY-2001 preliminary top line Phase I clinical data at the 13th International Conference on Alzheimer's and Parkinson's Diseases in Vienna, Austria 40
  • Jan 25, 2017: AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy 40
  • Jan 25, 2017: Voyager Therapeutics Announces Publication of Vectored Anti-Tau Monoclonal Antibody Study in The Journal of Neuroscience 41
  • Jan 16, 2017: ORYZON Announces Expansion of its Scientific Advisory Board 42
  • Jan 10, 2017: UK Regulatory Approval for Alzheimer's Disease Clinical Trial - XanADu 42
  • Jan 09, 2017: Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer's disease patients 42
  • Jan 09, 2017: NeuroGenetic Pharmaceuticals Completes Phase 1 Clinical Trials for NGP 555 to Treat and Prevent Alzheimer's Disease; Shown as Safe and Well-Tolerated in Healthy Volunteers 43
  • Jan 03, 2017: FDA Approval to Commence Alzheimers Disease Clinical Trial 43
  • Dec 27, 2016: Investigational new drug for Alzheimer's scheduled for first study in humans 43
  • Clinical Trial Profile Snapshots 45

Appendix 831

  • Abbreviations 831
  • Definitions 831
  • Research Methodology 832
  • Secondary Research 832
  • About GlobalData 833
  • Contact Us 833
  • Source 833

List of Tables

List of Tables

  • Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
  • Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13
  • Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14
  • Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 16
  • Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
  • Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 21
  • Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22
  • Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase, 2017* 24
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 25
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
  • Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
  • Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
  • Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 29
  • Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
  • Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
  • Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32

List of Figures

List of Figures

  • Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Alzheimer's Disease Therapeutics, Global, Clinical
Back to Top